Steve Berman News
-
Toyota Motor Corp. and lawyers suing the company persuaded a judge to give preliminary approval to a $1.1 billion settlement of claims that recalls for unintended acceleration hurt the value of U.S. customers’ vehicles.
-
Toyota Motor Corp. rose in the U.S. and Japan after Asia’s largest automaker said it’s taking a $1.1 billion charge to settle claims that recalls for unintended acceleration hurt the value of U.S. customers’ vehicles.
-
Toyota Motor Corp., Asia’s biggest automaker, will take a $1.1 billion charge to settle U.S. consumer claims that the value of their vehicles diminished because of recalls related to unintended acceleration.
-
The federal judge overseeing sudden- acceleration lawsuits against Toyota Motor Corp. appointed 21 plaintiffs’ lawyers to manage litigation involving U.S. claims.
-
The federal judge overseeing sudden- acceleration lawsuits against Toyota Motor Corp. appointed 21 plaintiffs’ lawyers to manage litigation involving U.S. claims.
-
Charles Schwab Corp. wouldn’t pay more under a revised accord to resolve shareholder lawsuits over losses in its YieldPlus mutual fund than under a $235 million settlement announced in May, a lawyer for investors said.
-
Barclays Plc was sued by an investor who claimed her futures-trading business was harmed by the bank’s admitted manipulation of the Euro Interbank Offered Rate.
-
A former Countrywide Financial Corp. manager whose fraud suit contributed to the mortgage industry’s $25 billion settlement with federal and state regulators received about $14.5 million for his efforts, his lawyers said.
-
Rajat Gupta, the former Goldman Sachs Group Inc. director once accused of feeding inside information to Galleon Group LLC’s Raj Rajaratnam, will face federal charges, a person familiar with the matter said, making him the highest-ranking executive to be named in the probe.
-
Hedge fund FrontPoint Partners LLC employees were allegedly tipped by a French doctor working as a consultant for Human Genome Sciences Inc. on the results of trials for the hepatitis-C drug Albuferon, a person familiar with the matter said.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page